iwCLL

1-888-476-9129 info@bioascend.com

Menu
2017 Presentations

Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Compatible Donors in Younger High Cytogenetic Risk CLL Patients Results in Very High Long-Term Progression-Free Survival and May Therefore Favorably Compete With Sequential Targeted Therapy


Michael van Gelder